A Clinical Stage Fc-engineered anti-CTLA-4 Antibody with Improved Therapeutic Potential for the Treatment of Patients with Advanced Malignancies
Steven J. O’Day, M.D., Executive Director of the John Wayne Cancer Institute and Cancer Clinic, and Director of Providence Los Angeles Regional Research, will be presenting Agenus NextGen CTLA-4 Antibody (AGEN1181) Data at the American Society of Clinical Oncology (ASCO) upcoming ASCO2020 Virtual Scientific Program to be held May 29-31, 2020.
AGEN1181 is a multifunctional Fc-engineered next generation anti-CTLA-4 antibody which has been designed to improve upon the safety and efficacy shown with first-generation CTLA-4 antibodies.
Don’t miss Dr. O’Day’s presentation to learn about the data and how it’s benefiting a broad population of cancer patients.
Friday, May 29, 2020
Presentations will be available for on-demand viewing online beginning May 29, 2020 at 8:00AM ET